Please use this identifier to cite or link to this item:
|Title:||Graphene oxide nanoplatelets potentiate anticancer effect of cisplatin in human lung cancer cells||Authors:||Nur Farhanah Rosli
Fisher, Adrian C.
|Keywords:||Science::Biological sciences||Issue Date:||2019||Source:||Nur Farhanah Rosli, Fojtů, M., Fisher, A. C. & Pumera, M. (2019). Graphene oxide nanoplatelets potentiate anticancer effect of cisplatin in human lung cancer cells. Langmuir, 35(8), 3176-3182. https://dx.doi.org/10.1021/acs.langmuir.8b03086||Project:||SERC A1783c0005||Journal:||Langmuir||Abstract:||Graphene oxide (GO) has been widely explored by many in drug delivery strategies and toxicity assays. The toxicity of graphene oxide depends on the size of the sheets. Smaller sheets show lower toxicity, a quality which is essential for utilization in biomedical applications. However, despite vast research on GO, anticancer properties and drug carrier capabilities of graphene oxide nanoplatelets have yet to be fully explored. Herein, we have uniquely prepared graphene oxide nanoplatelets (GONPs) from well-defined stacked graphite nanofibers (SGNF) with a base of 50 × 50 nm2 for toxicity and drug potentiation studies when coadministered with the chemotherapeutic drug cisplatin (CP) in human lung cancer cells, A549 cells. Results obtained from our studies have found that not only were GONPs able to act as drug carriers, but they can also significantly potentiate anticancer effect of CP in A549 cells.||URI:||https://hdl.handle.net/10356/151212||ISSN:||0743-7463||DOI:||10.1021/acs.langmuir.8b03086||Rights:||© 2019 American Chemical Society. All rights reserved.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SPMS Journal Articles|
Updated on Oct 15, 2021
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.